<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Guardant Health Inc — News on 6ix</title>
<link>https://6ix.com/company/guardant-health-inc</link>
<description>Latest news and press releases for Guardant Health Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 20:02:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/guardant-health-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835774c78dffbe2df0f7957.webp</url>
<title>Guardant Health Inc</title>
<link>https://6ix.com/company/guardant-health-inc</link>
</image>
<item>
<title>Goosehead Insurance, Inc. Announces First Quarter 2026 Results</title>
<link>https://6ix.com/company/guardant-health-inc/news/goosehead-insurance-inc-announces-first-quarter-2026-results</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/goosehead-insurance-inc-announces-first-quarter-2026-results</guid>
<pubDate>Wed, 22 Apr 2026 20:02:00 GMT</pubDate>
<description>– Total Revenue Increased 23% and Core Revenue* Grew 15% over the Prior-Year Period –– Total Written Premium increased 13% to $1.1 billion over the Prior-Year Period –– Net Income of $8.0 million versus Net Income of $2.6 million a year ago –– Adjusted EBITDA* up 57% over Prior-Year Period to $24.4 million –– Repurchased $49.8 million of shares during the quarter at an average price of $50.54 – WESTLAKE, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- Goosehead Insurance, Inc. (“Goosehead” or the “Com</description>
</item>
<item>
<title>Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Thu, 16 Apr 2026 20:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., April 16, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.</description>
</item>
<item>
<title>Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-healths-infinityai-real-world-evidence-supports-approval-of-enhertur-for-previously-treated-patients-with-her2-positive-metastatic-solid-tumors-in-japan</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-healths-infinityai-real-world-evidence-supports-approval-of-enhertur-for-previously-treated-patients-with-her2-positive-metastatic-solid-tumors-in-japan</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>This milestone underscores the power of Guardant Health’s InfinityAI platform and real-world data to enable innovative evidence generation in rare</description>
</item>
<item>
<title>Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data</title>
<link>https://6ix.com/company/guardant-health-inc/news/verana-health-and-guardant-health-partner-to-advance-precision-medicine-with-real-world-data</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/verana-health-and-guardant-health-partner-to-advance-precision-medicine-with-real-world-data</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development SAN</description>
</item>
<item>
<title>Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-to-present-28-abstracts-highlighting-advances-in-tumor-typing-therapy-selection-and-expanded-utility-of-multiomic-tissue-and-liquid-biopsy-testing-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-to-present-28-abstracts-highlighting-advances-in-tumor-typing-therapy-selection-and-expanded-utility-of-multiomic-tissue-and-liquid-biopsy-testing-at-aacr-2026</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Guardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoring Studies show strong</description>
</item>
<item>
<title>Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-launches-shield-multi-cancer-detection-mcd-test-in-multiple-markets-in-asia-with-manulife-partnership</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-launches-shield-multi-cancer-detection-mcd-test-in-multiple-markets-in-asia-with-manulife-partnership</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the</description>
</item>
<item>
<title>Manulife Announces Exclusive Partnership with Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia</title>
<link>https://6ix.com/company/guardant-health-inc/news/manulife-announces-exclusive-partnership-with-guardant-health-to-bring-the-shield-multi-cancer-detection-test-to-customers-across-asia-1</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/manulife-announces-exclusive-partnership-with-guardant-health-to-bring-the-shield-multi-cancer-detection-test-to-customers-across-asia-1</guid>
<pubDate>Mon, 16 Mar 2026 03:00:00 GMT</pubDate>
<description>Manulife today announced an exclusive partnership with Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, becoming the first insurer in Asia to offer Guardant Health's Shield Multi-Cancer Detection (MCD) test to customers in Hong Kong, the Philippines, and Singapore. Under the partnership, Manulife's customers will have exclusive access to the Shield MCD test in these three launch markets in 2026, marking the first introduction of this innovative test in Asia to Manulife c</description>
</item>
<item>
<title>New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare</title>
<link>https://6ix.com/company/guardant-health-inc/news/new-guardant-healthharris-poll-survey-shows-92percent-of-all-eligible-americans-believe-colorectal-cancer-blood-tests-should-be-accessible-and-covered-similar-to-medicare</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/new-guardant-healthharris-poll-survey-shows-92percent-of-all-eligible-americans-believe-colorectal-cancer-blood-tests-should-be-accessible-and-covered-similar-to-medicare</guid>
<pubDate>Fri, 13 Mar 2026 12:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., March 13, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening, including new innovations like Shield™ by Guardant, a methylation partitioning cell-free DNA (mp-cfDNA) test and the first an</description>
</item>
<item>
<title>Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-healths-shield-blood-based-screening-test-for-colorectal-cancer-now-accessible-through-national-test-ordering-and-collection-network-of-quest-diagnostics</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-healths-shield-blood-based-screening-test-for-colorectal-cancer-now-accessible-through-national-test-ordering-and-collection-network-of-quest-diagnostics</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network</description>
</item>
<item>
<title>Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-launches-coast-to-coast-screening-tour-bringing-shield-colon-cancer-blood-test-to-over-100-communities-across-america-7</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-launches-coast-to-coast-screening-tour-bringing-shield-colon-cancer-blood-test-to-over-100-communities-across-america-7</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Shield Across America mobile screening tour launches during Colorectal Cancer Awareness Month to address nation’s dangerously low screening rates by bringing</description>
</item>
<item>
<title>Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened</title>
<link>https://6ix.com/company/guardant-health-inc/news/actor-and-cancer-advocate-patrick-dempsey-partners-with-guardant-health-to-raise-awareness-about-colorectal-cancer-screening-and-shield-blood-test-sharing-his-experience-getting-screened</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/actor-and-cancer-advocate-patrick-dempsey-partners-with-guardant-health-to-raise-awareness-about-colorectal-cancer-screening-and-shield-blood-test-sharing-his-experience-getting-screened</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>1 in 3 eligible Americans avoid colorectal cancer (CRC) screenings because traditional methods are viewed as unpleasant and inconvenient Guardant's</description>
</item>
<item>
<title>Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-outlook</guid>
<pubDate>Thu, 19 Feb 2026 21:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., February 19, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-launches-community-colorectal-193500633</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-launches-community-colorectal-193500633</guid>
<pubDate>Thu, 12 Feb 2026 19:35:00 GMT</pubDate>
<description>Ahead of Colorectal Cancer (CRC) Awareness Month in March, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of its Community Colorectal Cancer Screening Grant Program, designed to support community-led efforts to expand access to colorectal cancer screening throughout March.</description>
</item>
<item>
<title>Guardant Health to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-participate-upcoming-investor-210500006</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-participate-upcoming-investor-210500006</guid>
<pubDate>Tue, 03 Feb 2026 21:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., February 03, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.</description>
</item>
<item>
<title>Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions</title>
<link>https://6ix.com/company/guardant-health-inc/news/largest-published-study-molecular-residual-130500071</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/largest-published-study-molecular-residual-130500071</guid>
<pubDate>Mon, 02 Feb 2026 13:05:00 GMT</pubDate>
<description>PALO ALTO, Calif. & ROCHESTER, Minn., February 02, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncolog</description>
</item>
<item>
<title>Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-report-fourth-quarter-210500847</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-report-fourth-quarter-210500847</guid>
<pubDate>Thu, 29 Jan 2026 21:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., January 29, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.</description>
</item>
<item>
<title>Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-receives-fda-approval-130500856</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-receives-fda-approval-130500856</guid>
<pubDate>Thu, 22 Jan 2026 13:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., January 22, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.</description>
</item>
<item>
<title>Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-announces-multi-strategic-130500395</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-announces-multi-strategic-130500395</guid>
<pubDate>Mon, 19 Jan 2026 13:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., January 19, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform.</description>
</item>
<item>
<title>Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-announces-preliminary-fourth-quarter-and-full-year-2025-results-2026</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-announces-preliminary-fourth-quarter-and-full-year-2025-results-2026</guid>
<pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
<description>Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH),</description>
</item>
<item>
<title>Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families</title>
<link>https://6ix.com/company/guardant-health-inc/news/guardant-health-shield-blood-test-130500942</link>
<guid isPermaLink="true">https://6ix.com/company/guardant-health-inc/news/guardant-health-shield-blood-test-130500942</guid>
<pubDate>Thu, 08 Jan 2026 13:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., January 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and their families through TRICARE, the U.S. military’s health insurance coverage, with no copay for average-risk individuals ages 45 and older.</description>
</item>
</channel>
</rss>